In addition, a small subset of patients with EGFR/ALK gene mutations received ICI-containing treatment regimens, which was consistent with the recommendations of clinical guidelines for advanced NSCLC during the study enrollment period. Here, EGFR is linked to non-small cell lung carcinoma.